Aytu Biopharma (AYTU) investor relations material

Business overview and strategy

• Focused on central nervous system conditions, primarily major depressive disorder (MDD) and ADHD, with a portfolio built through M&A and a recent shift toward launching EXXUA for adult depression.

• Legacy ADHD and pediatric products have been deprioritized in promotion as they near loss of exclusivity, with commercial efforts now centered on EXXUA.

• Internal sales force of about 40 representatives targets high-volume, brand-centric psychiatry practices, supported by contract sales reps expected to transition to full-time roles.

• Distribution strategy leverages independent pharmacies and select regional grocery chains to streamline patient access and minimize copays.

• Emphasis on patient adherence and repeatability through a frictionless prescription process, supporting chronic illness management.

Product and market insights

• EXXUA is the first and only FDA-approved 5-HT1A agonist for MDD, offering a novel mechanism that avoids common SSRI side effects like sexual dysfunction and weight gain.

• MDD represents a $22 billion gross revenue market in the U.S., with 21 million affected and 345 million annual prescriptions, mostly treated with SSRIs.

• EXXUA demonstrated efficacy in two pivotal phase III studies, showing significant improvement over placebo as early as week three, with minimal side effects and no warnings for sexual dysfunction or weight gain.

• Early commercial performance of EXXUA is strong, with increasing prescriptions and shipments, and expectations for it to become a key revenue driver.

• ADHD and pediatric portfolios remain durable, providing cash flow to support EXXUA’s growth despite anticipated gradual revenue decline.

Financial highlights and outlook

• Trailing 12-month revenue: ADHD portfolio just under $49 million, pediatric portfolio just over $5 million, and EXXUA contributing $2.6 million, mostly in the March quarter.

• Net revenue for fiscal 2026 includes $2.4 million from EXXUA, with expectations that EXXUA will offset ADHD portfolio declines over the next 12–15 months.

• Significant expense reductions and operational improvements have been made, with launch costs for EXXUA impacting EBITDA but expected to yield benefits in fiscal 2027 and 2028.

• Ended March 31, 2026, with $26.7 million in cash and cash equivalents, no high-interest debt, and no anticipated need to raise capital to reach profitability with EXXUA.

• Strong shareholder base with major healthcare-focused investors participating in recent capital raises, and a total of 19.5 million shares outstanding when including pre-funded warrants.